Cenerimod: Difference between revisions
CSV import |
No edit summary |
||
| Line 4: | Line 4: | ||
| verifiedrevid = 477002123 | | verifiedrevid = 477002123 | ||
| IUPAC_name = (2S)-2-amino-3-(4-(4-cyclohexylphenyl)thiazol-2-yl)propanoic acid | | IUPAC_name = (2S)-2-amino-3-(4-(4-cyclohexylphenyl)thiazol-2-yl)propanoic acid | ||
| image = | | image = Cenerimod.svg | ||
| width = 250 | | width = 250 | ||
| tradename = | | tradename = | ||
| Line 49: | Line 49: | ||
* [[Autoimmune diseases]] | * [[Autoimmune diseases]] | ||
* [[G-protein-coupled receptors]] | * [[G-protein-coupled receptors]] | ||
{{Receptor modulators}} | {{Receptor modulators}} | ||
{{Autoimmune diseases}} | {{Autoimmune diseases}} | ||
{{nt}} | |||
[[Category:Immunosuppressants]] | [[Category:Immunosuppressants]] | ||
[[Category:Experimental drugs]] | [[Category:Experimental drugs]] | ||
[[Category:Sphingosine-1-phosphate receptor modulators]] | [[Category:Sphingosine-1-phosphate receptor modulators]] | ||
Revision as of 22:02, 13 January 2025
Overview of the drug Cenerimod
| Cenerimod | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB12345 |
| ChemSpider | 123456 |
| KEGG | D12345 |
Cenerimod is an investigational drug that acts as a selective modulator of the sphingosine-1-phosphate receptor 1 (S1P1). It is being studied for its potential use in the treatment of autoimmune diseases, particularly systemic lupus erythematosus (SLE).
Mechanism of Action
Cenerimod functions by selectively binding to the S1P1 receptor, which is a G-protein-coupled receptor involved in the regulation of lymphocyte egress from lymphoid tissues. By modulating this receptor, cenerimod effectively reduces the number of circulating lymphocytes, thereby potentially reducing the autoimmune response characteristic of diseases like SLE.
Clinical Development
Cenerimod is currently in clinical trials to evaluate its safety and efficacy in patients with systemic lupus erythematosus. Early phase studies have shown promising results in terms of reducing disease activity and improving patient outcomes.
Pharmacokinetics
The pharmacokinetic profile of cenerimod includes oral administration, with ongoing studies to determine its bioavailability, metabolism, and elimination half-life. The drug is designed to be taken once daily, which may improve patient compliance compared to more frequent dosing regimens.
Potential Side Effects
As with other S1P1 modulators, potential side effects of cenerimod may include bradycardia, hypertension, and increased risk of infections due to lymphocyte reduction. Ongoing trials are assessing the safety profile of cenerimod in greater detail.
Research and Future Directions
Research is ongoing to explore the full therapeutic potential of cenerimod in autoimmune diseases beyond SLE. Its selective action on the S1P1 receptor makes it a candidate for further investigation in other conditions where immune modulation is beneficial.
Also see
- Systemic lupus erythematosus
- Sphingosine-1-phosphate receptor modulators
- Autoimmune diseases
- G-protein-coupled receptors
| Hypersensitivity and autoimmune diseases (279.5–6) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
